Parts of the EU Pharma Package already in Force

Recent information from internal EU coordination meetings reveals an example of unfortunate and inconsistent communication by EU authorities regarding the timeline of the new EU pharmaceutical legislation.

In all public communications to date, the message was consistent: the new pharmaceutical legislation would only enter into force 18-36 months after publication in the EU Official Journal. This statement has been widely repeated in presentations, stakeholder briefings, and conference discussions.

However, the minutes of a recent Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) meeting now show that the legislation will, in fact, follow a staggered application model:

• Day 0 (entry into force): The "Union List of Critical Medicines" will be "immediately applicable".
• Six months: "Chapter X - Availability and Security of Supply" will become applicable six months after entry into force.
• Later stages: Further parts of the legislation will follow step by step.

While staggered entry into force is not unusual in EU legislation, the gap between public-facing communication and internal briefings is striking. Stakeholders were led to believe that no practical impact would occur for at least 18 months, whereas key obligations and mechanisms will apply much earlier.

Adding to the uncertainty, a final, consolidated legal text is still not available, making it difficult for companies, authorities, and supply chain actors to prepare adequately.

For stakeholders across the pharmaceutical sector, this episode underlines a familiar problem: Regulatory change is no longer just about what is decided, but how and when it is communicated.